Radiopharmaceutical leaders urge pharma to adopt more aggressive cancer dosing
Louise Emmett and fellow specialists argue that drug makers should use radiopharmaceuticals more boldly, despite recent safety setbacks.
Emmett, a prominent figure in radiopharmaceutical development, says the oncology field could benefit from more frequent dosing of these agents. She notes collaborations with global firms such as AstraZeneca and Novartis. However, some experimental drugs have unintentionally harmed kidneys, liver or bone marrow, prompting at least one company to halt a program and creating challenges for others.
Why it matters
The push for bolder radiopharmaceutical use could reshape cancer treatment but raises safety and regulatory challenges.
In this story
radiopharmaceuticalscancer therapydosing frequencyorgan toxicitydrug developmentAstraZenecaNovartisLouise Emmett
